Form 4: Zenas BioPharma Executive Granted Stock Options
SEC Form 4 Filing
Orlando Oliveira, Chief Commercial Officer of Zenas BioPharma, Inc., was granted stock options on December 16, 2024.
Summary
- Orlando Oliveira, the Chief Commercial Officer of Zenas BioPharma, Inc., received stock options on December 16, 2024.
- The stock options grant gives Oliveira the right to buy 7,775 shares of Zenas BioPharma's common stock at an exercise price of $8.77 per share.
- The options vest over a period of 4 years, with 25% vesting on July 1, 2025, and the remaining shares vesting in equal monthly installments over the following 36 months, contingent upon continued service.
- The options expire on December 15, 2034.
Sentiment
Score: 7
Explanation: The document is a routine disclosure of stock option grants, which is generally viewed as a positive sign of incentivizing management. The sentiment is neutral to slightly positive.
Positives
- The granting of stock options to the Chief Commercial Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's success.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biopharmaceutical industry to attract and retain key executives and align their interests with those of shareholders. This grant is a standard form of executive compensation.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in the biotechnology industry.
- The vesting schedule and exercise price appear to be within typical ranges for similar companies and executive roles.
- Comparing the number of shares granted and the exercise price to those of peer companies would provide a more detailed assessment of the grant's competitiveness.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Commercial Officer to drive company growth.
- The grant has no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date of the stock option grant. |
| 07/01/2025 | First vesting date for 25% of the stock options. |
| 12/15/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.